Why Apogee Therapeutics Stock Is On Investors’ Radar

Apogee Therapeutics (APGE) recently attracted attention after its strong past 3 months return, which contrasts with relatively flat moves over the past week and month. Investors are weighing that performance against its current clinical stage profile.

At a latest share price of US$134.09, Apogee Therapeutics has seen share price momentum cool in the very short term. However, its 90 day share price return of 66.06% and one year total shareholder return of 255.21% point to a strong longer run move that investors are now reassessing against clinical and funding risks.

If you are looking beyond Apogee Therapeutics for other fast moving biotech ideas, it could be worth scanning a curated set of healthcare focused AI opportunities through the 41 healthcare AI stocks

After Apogee Therapeutics’ sharp 90 day and one year gains, the stock now trades near its recent highs while still being a loss making, clinical stage company. Does that balance of momentum and risk still favour new buyers?

Preferred Price-To-Book Multiple Of 8x For Apogee Therapeutics: Is It Justified?

Apogee Therapeutics currently trades at a P/B ratio of 8x, which is well above the broader US biotechs industry average but below its closer peer group.

The P/B ratio compares a company’s market value to its book value, which is its net assets on the balance sheet. For a clinical stage biotech like Apogee Therapeutics that reports a loss of $274.615m and effectively no revenue yet, investors often lean on P/B because traditional earnings based measures such as P/E are not meaningful.

At 8x book value, investors are assigning a relatively rich valuation to Apogee Therapeutics compared to the US biotechs industry average of 2.4x. However, within its more specific peer group, the average P/B is 19.4x. This makes Apogee Therapeutics look cheaper on this single metric. That split hints at a stock that screens expensive for the sector overall while still trading at a discount to higher priced peers that share similar characteristics.

Result: Price-to-book of 8x (ABOUT RIGHT)

However, investors still face clinical trial risk and ongoing losses of $274.615m, which could pressure Apogee Therapeutics if funding conditions or study outcomes weaken.

Next Steps

The mix of excitement and caution around Apogee Therapeutics will not be settled by one metric or viewpoint, so it helps to check the underlying data yourself and move promptly while sentiment is still forming. To see how the balance of concerns and potential upsides stacks up in one place, review the 1 key reward and 4 important warning signs

Looking For More Ideas Beyond Apogee Therapeutics?

If you like what you see with Apogee Therapeutics but want a broader watchlist, it makes sense to cast the net wider using focused sets of stocks.

• Target potential mispriced opportunities by scanning a curated set of companies that appear cheap on quality metrics through the 55 high quality undervalued stocks
• Strengthen your income focus by reviewing companies that combine higher yields with resilient track records using the 9 dividend fortresses
• Protect your downside by filtering for companies that score well on resilience and risk using the 81 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.